AVISE CTD contains the patented Lupus (SLE) biomarkers, CB-CAPs, which help to offer a 22% greater sensitivity compared to C3/C4, and 48% greater sensitivity compared to anti-dsDNA. Erythrocyte-bound C4d is a patented and stable lupus biomarker that measures complement activation to help physicians diagnose lupus and monitor activity..